Research Gate reveals that Mikhail Blagosklonny is a scientist who studied cancer and aging at the First Pavlov State Medical University of St. Petersburg graduating with both a doctor of medicine and doctor of philosophy in internal organs, medical specialty, and medical experiments, heart and its related ailments respectively. Currently, he is a professor of oncology at Roswell Park Institute in New York, United States.
Before being appointed to this position Blagosklonny in 2002, he had been named an associate professor at New York Medical College as a professor of medicine. He then became a highly-ranked scientist at Ordway Research Institute. Mikhail Blagosklonny mostly researches on cancer treatment and how aging contributes to vulnerability to the menace.
Besides the oncology, Mr. Makhail is an editor of different publications and was ranked among those who extensively researched and substantially wrote about aging about cancer in 2013. During this time, he was the editor in chief of cell cycle and oncotarget. He also part of the 700forescience, a movement by specialists who use their knowledge and skills to support research projects in biotechnology.
He advocates for use rapamycin as a medication for extending life when one age. This is a remedy for his hypothesis on the likely role of TOR signaling at old age and cancer susceptibility.
Important to remember again is that 2014 is the year that will go in annals of history as the period in which the able professor Mikhail Blagosklonny researched and found out that there could be an immune booster for the old people who stand a risk of acquiring cancer due to their low immunity.
Lastly, at Roswell Park Institute in New York, Professor Mikhail Blagosklonny is a researcher in hematology, oncology, and carries out clinical experiments to ascertain whether the used equipment, method of use and the medication prescribed and administered is safe to human beings.
According to Impact Journals, Mikhail Blagosklonny believes that the will come a time when cancer will no longer be a health threat to all individuals in the international platform.